Mirae Asset Global Investments Co. Ltd. Increases Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 2.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,940 shares of the company’s stock after buying an additional 524 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Kymera Therapeutics were worth $584,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in KYMR. Allspring Global Investments Holdings LLC increased its holdings in shares of Kymera Therapeutics by 33.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 5,183 shares of the company’s stock valued at $72,000 after purchasing an additional 1,310 shares during the period. Arizona State Retirement System acquired a new position in shares of Kymera Therapeutics in the third quarter valued at about $142,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Kymera Therapeutics by 352.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,423 shares of the company’s stock valued at $164,000 after purchasing an additional 5,002 shares during the period. Hsbc Holdings PLC acquired a new position in shares of Kymera Therapeutics in the third quarter valued at about $185,000. Finally, Exchange Traded Concepts LLC increased its holdings in shares of Kymera Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 7,359 shares of the company’s stock valued at $187,000 after purchasing an additional 1,866 shares during the period.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, insider Jared Gollob sold 46,137 shares of the stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $35.50, for a total transaction of $1,637,863.50. Following the completion of the transaction, the insider now owns 74,709 shares of the company’s stock, valued at $2,652,169.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Kymera Therapeutics news, insider Jared Gollob sold 46,137 shares of the stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $35.50, for a total transaction of $1,637,863.50. Following the completion of the transaction, the insider now owns 74,709 shares of the company’s stock, valued at $2,652,169.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bruce Booth sold 71,764 shares of the stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $40.46, for a total value of $2,903,571.44. Following the transaction, the director now directly owns 806,697 shares of the company’s stock, valued at approximately $32,638,960.62. The disclosure for this sale can be found here. Insiders sold 474,051 shares of company stock valued at $19,624,211 over the last quarter. 16.67% of the stock is currently owned by insiders.

Kymera Therapeutics Trading Down 5.3 %

Shares of KYMR stock opened at $33.35 on Friday. The company has a market capitalization of $2.04 billion, a P/E ratio of -13.23 and a beta of 2.27. The business’s 50 day moving average is $39.02 and its two-hundred day moving average is $28.41. Kymera Therapeutics, Inc. has a 12-month low of $9.60 and a 12-month high of $45.31.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, February 22nd. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.19. Kymera Therapeutics had a negative return on equity of 34.83% and a negative net margin of 187.00%. The company had revenue of $47.90 million for the quarter, compared to the consensus estimate of $41.94 million. During the same quarter in the prior year, the business posted ($0.60) earnings per share. Kymera Therapeutics’s revenue for the quarter was up 197.5% on a year-over-year basis. On average, research analysts predict that Kymera Therapeutics, Inc. will post -3.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on KYMR. Bank of America lowered Kymera Therapeutics from a “buy” rating to a “neutral” rating and cut their price objective for the company from $45.00 to $30.00 in a report on Wednesday, January 3rd. Piper Sandler upped their target price on Kymera Therapeutics from $39.00 to $56.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 27th. Oppenheimer assumed coverage on Kymera Therapeutics in a research note on Monday. They issued an “outperform” rating and a $53.00 target price on the stock. Stifel Nicolaus upped their target price on Kymera Therapeutics from $35.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, February 23rd. Finally, Wolfe Research assumed coverage on Kymera Therapeutics in a research note on Thursday, February 15th. They issued a “peer perform” rating on the stock. Six analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $41.20.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.